10-K: Northwest Biotherapeutics Reports 2024 Results, Highlights Progress on DCVax and Regulatory Milestones

Northwest Biotherapeutics provides an update on its 2024 activities, including progress on its DCVax platform, regulatory submissions, and manufacturing developments.

Summary

• Northwest Biotherapeutics, a biotechnology company focused on developing personalized immune therapies for cancer, has released its Form 10-K for the year ended December 31, 2024.
• The company's lead product candidate, DCVax-L, is designed to treat solid tumor cancers and has completed a Phase III trial for Glioblastoma multiforme brain cancer (GBM).
• A Marketing Authorization Application (MAA) for commercial approval in the U.K. was submitted on December 20, 2023.
• The company is also planning clinical trials for DCVax-L for other solid tumor cancers and preparing for Phase II trials of DCVax-Direct, designed to treat inoperable solid tumors.
• The company incurred a net loss of $83.8 million for the year ended December 31, 2024, and net cash used in operations was $57.0 million.
• Research and development expenses were $34.9 million, and general and administrative expenses were $33.0 million.
• The company has 48 issued patents and 60 pending patent applications worldwide as of December 31, 2024.
• The company's auditors have issued a going concern audit opinion.
• As of March 28, 2025, the company had 1,390,753,061 shares of common stock outstanding.
• The company is involved in ongoing litigation, including a lawsuit against certain market makers and derivative lawsuits.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in regulatory progress and product development, the significant net loss and going concern warning temper the overall sentiment. The ongoing litigation and need for continuous fundraising add further uncertainty.

Positives

• The company submitted a Marketing Authorization Application (MAA) for DCVax-L in the U.K.
• The Sawston facility received its first regulatory inspection under the MIA license.
• The company completed an upgraded Flaskworks machine for GMP prototypes.
• The company completed a License and Supply Agreement with a company for a TLR agonist booster agent.
• The company is actively engaged in the Marketing Authorization Application (MAA) review process and inspections.
• The company is planning for possible initial commercialization.
• The company is developing streamlined Grade C lab plan for the Sawston facility with faster timeframe and substantially reduced capital cost.
• The company is designing initial DCVax-Direct clinical trials, in collaboration with leading clinicians, and completion of drafting of initial protocols for upcoming IND submissions.
• The company is vigorously prosecuting patent applications; numerous new patents granted or allowed.
• The company is making positive progress in litigation.

Negatives

• The company incurred a net loss of $83.8 million for the year ended December 31, 2024.
• The company's auditors have issued a going concern audit opinion.
• The company will need to raise substantial funds, on an ongoing basis, for general corporate purposes and operations, including our clinical trials.
• The market price of our common stock is volatile and can be adversely affected by several factors.
• Our Common Stock is considered a penny stock and may be difficult to sell.

Risks

• The company will need substantial additional funding, on an ongoing basis, and such funding may not be available or may not be available on acceptable terms.
• The company is likely to continue to incur substantial losses and may never achieve profitability.
• Maintaining a strong control environment, free of material weaknesses, is dependent on our ability to retain an adequate number of qualified personnel and/or consultants to perform such control activities and other factors.
• As a company with a novel technology and unproven business strategy, an evaluation of our business and prospects is difficult.
• The company will need to expand our management and technical personnel as our operations progress, and we may not be able to recruit such additional personnel and/or retain existing personnel.
• The company relies at present on third-party contract manufacturers, which may result in issues with manufacturing agreements, capacity limitations and/or supply disruptions, and/or issues with product equivalency.
• The company's technology is novel, involves complex immune system elements, and may not prove to be effective.
• Clinical trials for our product candidates are expensive and time consuming, and their outcome is uncertain.
• The company has limited experience in conducting and managing clinical trials, or collecting, confirming and analyzing trial data, and we rely on third parties to conduct these activities.
• The company may fail to comply with regulatory requirements.
• Regulatory approval of our product candidates may be withdrawn at any time.
• The company's operations under early access programs may not be successful.
• The company may not be successful in negotiating reimbursement.
• The company's product candidates will require a different distribution model than conventional therapeutic products, and this may impede commercialization of our product candidates.
• The company's product candidates will require different marketing and sales methods and personnel than conventional therapeutic products; also, we lack sales and marketing experience; these factors may result in significant difficulties in commercializing our product candidates.
• The availability and amount of potential reimbursement for our product candidates by government and private payers is uncertain and may be delayed and/or inadequate.
• Competition in the biotechnology and biopharmaceutical industry is intense, rapidly expanding and most of our competitors have substantially greater resources than we do.
• The company may be exposed to potential product liability claims, and our existing insurance may not cover these claims, in whole or in part; in addition, insurance against such claims may not be available to us on reasonable terms in the future, if at all.
• The company may be subject to environmental regulatory requirements, and could fail to meet such requirements, and we do not carry insurance against environmental damage or injury claims.
• Collaborations play an important role in our business and could be vulnerable to competition or termination.
• The company may have disputes with our collaborators, which could be costly and time consuming; failure to successfully defend our rights could seriously harm our business, financial condition and operating results; we intend to continue to enter into collaborations in the future; however, we may be unable to successfully negotiate any additional collaboration and any of these relationships, if established, may not be scientifically or commercially successful.
• The company's business could be adversely affected by new legislation and/or product related issues.
• The company's business could be adversely affected by animal rights activists.
• Multiple late-stage clinical trials of DCVax-L for GBM, our lead product, may be required before we can obtain regulatory approval.
• The company may not receive regulatory approvals for our product candidates or there may be a delay in obtaining such approvals.
• The company may not obtain or maintain the benefits associated with orphan drug status, including market exclusivity.
• The company's intellectual property rights may be overturned, narrowed or blocked, and may not provide sufficient commercial protection for our product candidates, or third parties may infringe upon our intellectual property.
• The company may be exposed to claims or lawsuits that our products infringe patents or other proprietary rights of other parties.
• DCVax is our only technology in clinical development.
• The market price of our common stock is volatile and can be adversely affected by several factors.
• Our Common Stock is considered a penny stock and may be difficult to sell.
• The requirements of the Sarbanes-Oxley Act of 2002 and other U.S. securities laws impose substantial costs and may drain our resources and distract our management.
• The company does not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our common stock must come from increases in the market price of our common stock.
• Our certificate of incorporation and bylaws and Delaware law, have provisions that could discourage, delay or prevent a change in control.
• A substantial number of shares of common stock may be sold in the market, which may depress the market price for our common stock.
• The company may have claims and lawsuits against us that may result in adverse outcomes.

Future Outlook

The company plans to conduct clinical trials of DCVax-L for other solid tumor cancers in the future, when resources permit, and is working on preparations for Phase II trials of DCVax-Direct as resources permit.

Management Comments

• The Company is actively engaged in the ongoing process, and the Company has decided not to attend ASCO this year in order to stay focused on interactions with the MHRA and efforts to move forward as quickly as possible.
• As previously reported, the Company plans to announce the results when the MHRA review and decision-making is finished and does not plan to provide interim updates.

Industry Context

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products; a large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer.

Comparison to Industry Standards

• The company faces competition from companies developing new treatments for brain cancer, including immune therapies, small molecule drugs, and biologics.
• Competitors include Roche Holding AG (Avastin), Eisai Co. Ltd. (Gliadel), Merck & Co., Inc. (Temodar), and Novocure (Optune electro-therapy device).
• Many competitors have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing and sales than we do.
• Smaller or early-stage companies may also prove to be significant competitors, particularly if they enter into collaborative arrangements with large and established companies.

Legal Proceedings

• On December 1, 2022, the company filed a Complaint in the United States District Court for the Southern District of New York against certain market makers, alleging manipulation of the company's stock.
• Three stockholders filed derivative lawsuits against the company and certain of its directors and officers, alleging breach of fiduciary duties and unjust enrichment by director and officer compensation awarded in 2020.

Related Party Transactions

• The company has ongoing transactions with Advent BioServices, a related party, for manufacturing and related services for DCVax-L products.
• The company entered into a Sub-lease Agreement with Advent for a portion of the Sawston facility.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity issuances.
• Employees' job security is tied to the company's ability to secure funding and achieve commercial success.
• Patients may benefit from the development and potential approval of DCVax therapies.
• Suppliers and creditors are subject to the company's ability to meet its financial obligations.

Next Steps

• The company plans to conduct clinical trials of DCVax-L for other solid tumor cancers in the future, when resources permit.
• The company is working on preparations for Phase II trials of DCVax-Direct as resources permit.
• The company plans to obtain MHRA approval of the new pediatric brain cancer trial design and move forward with the trial in due course.
• The Company plans to submit both studies to the FDA in Q2 2025, and plans to announce the details after they have been cleared by the FDA.
• The Company plans to continue this lab research while the initial clinical trials of DCVax-Direct get under way, and then plans to select the most useful booster agent(s) or combination(s) to produce enhanced versions of DCVax products for testing in additional trial cohorts.
• The Company hopes to complete these negotiations during Q2 or Q3 2025.
• The next step in the litigation will be a status conference with the Court to set the discovery schedule for the case.

Key Dates

Keywords

DCVax, glioblastoma, biotechnology, immunotherapy, clinical trials, cancer, pharmaceuticals, patents, regulatory, MAA